Microneedle Transdermal Patches-A Novel Painless Approach with Improved Bioavailability for the Treatment of Diseases with Special Prevalence to Neonatal Infections

Abstract

Microneedle transdermal drug delivery systems (TDDS) present a compelling substitute for parenteral and oral administration methods in the treatment of several illnesses. The past several decades have seen a revolution in technology that has changed the production of micro-structured devices, including the development of microneedles for transdermal patches. These devices are used to deliver drugs, proteins, insulin, antibiotics, vaccinations, and other therapies through the skin. They are proven to be beneficial for the prevention of newborn infections. Successful treatments for conditions like cancer, diabetes, rheumatoid arthritis, Alzheimer’s disease, and migraines can be achieved with the use of transdermal microneedle patches. Microneedles have the potential to offer prolonged immunity, dosage sparing, and improved protection against viral challenges. The epidermis and dermis are immunologically rich layers, and because of the needles’ micron-size structure, these devices have shown to be significantly more effective at targeting these layers, indicating their potential utility in the creation of next-generation vaccines. Within the framework of developing vaccines. Microneedle transdermal patches’ main benefits are that they are easy to use, painless, and non-invasive. Here, we discuss the types of microneedle transdermal patches and how microneedle transdermal patches are now being used to treat infections in newborns and vaccination and as a more cost-effective self-administration approach. This also enhances the bioavailability when used in vaccination therapy. Next, we’ll go over how microneedle transdermal patches are currently used to treat a variety of illnesses effectively, including those that affect newborns.